However, the clinical efficacy of osimertinib in patients with NSCLC with other metastatic organs such as bone or liver remains unclear; although, patients with EGFR-mutant NSCLC have a higher frequency of bone metastasis than patients with EGFR-wild type [5, 19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.